Keen interest in EU biosimilar insulin guideline prompts another consultation round
This article was originally published in SRA
Executive Summary
Drug companies waiting for the new version of the European Medicines Agency's guideline on biosimilar insulin will have to be patient for a while longer because the document has been put out for a rare second public consultation1, nearly a year and a half after it was first released for comment2.